Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986205 reference · 3 trials · 1 indication
Measured by plasma concentration.
Measured by plasma concentration.
Measured by plasma concentration.
Measured by plasma concentration.
Measured by plasma concentration.
Measured by plasma concentration.
Measured by plasma concentration.
Measured by plasma concentration.
Measured by plasma concentration.
Measured by plasma concentration.
| Arm | Type | Description |
|---|---|---|
| Reference tablet followed by BMS-986205 tablet with free base | EXPERIMENTAL | BMS-986205 reference tablet (treatment period 1) followed by BMS-986205 tablet with free base (treatment period 2). |
| BMS-986205 tablet with free base followed by reference tablet | EXPERIMENTAL | BMS-986205 tablet with free base (treatment period 1) followed by BMS-986205 reference tablet (treatment period 2). |
| BMS-986205 intact tablet orally then crushed tablet orally | EXPERIMENTAL | Single, 100 mg dose |
| BMS-986205 crushed tablet orally, then intact tablet orally | EXPERIMENTAL | Single, 100 mg dose |
| BMS-986205 intact tablet orally then suspension via NG tube | EXPERIMENTAL | Single, 100 mg dose |
| BMS-986205 suspension via NG tube then intact tablet orally | EXPERIMENTAL | Single, 100 mg dose |
| BMS-986205 under fasted conditions then with high-fat meal. | EXPERIMENTAL | Single, 100 mg dose of BMS-986205 under fasted conditions (Day 1) followed by single, 100 mg dose of BMS-986205 with a high-fat meal (Day 15). |
| BMS-986205 with high-fat meal then under fasted conditions. | EXPERIMENTAL | Single, 100 mg dose of BMS-986205 with a high-fat meal (Day 1) followed by single, 100 mg dose of BMS-986205 under fasted conditions (Day 15). |
| BMS-986205 under fasted conditions then with light meal. | EXPERIMENTAL | Single, 100 mg dose of BMS-986205 under fasted conditions (Day 1) followed by single, 100 mg dose of BMS-986205 with a light meal (Day 15). |
| BMS-986205 with light meal then under fasted conditions. | EXPERIMENTAL | Single, 100 mg dose of BMS-986205 with a light meal (Day 1) followed by single, 100 mg dose of BMS-986205 under fasted conditions (Day 15). |
| Name | Type | Description |
|---|---|---|
| BMS-986205 reference tablet | DRUG | Single, 100 mg oral dose. |
| BMS-986205 tablet with free base | DRUG | Single, 100 mg oral dose. |
| BMS-986205 | DRUG | Single 100 mg dose on Day 1 and Day 15 |
Inclusion Criteria: * Signed, written informed consent. * Healthy male and female participants (not of childbearing potential), determined by medical history, physical examination, electrocardiograms (ECGs) and clinical laboratory tests. * Normal renal (kidney) function. * Body Mass Index (BMI) of ...
BMS-986205 is an investigational small molecule being studied for use in oncology, including advanced cancer, melanoma, and non-small cell lung cancer. It has also been evaluated in healthy participants for bioavailability studies. The drug is in Phase 1 clinical development and is not yet approved by the FDA.
BMS-986205 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical trials of this investigational oncology drug in combination with other immunotherapies such as nivolumab and ipilimumab.
BMS-986205 is in Phase 1 clinical development. All three completed trials for this drug were Phase 1 studies, including combination trials with nivolumab and ipilimumab in advanced cancers, a Japanese study in advanced tumors, and a bioavailability study in healthy participants.
BMS-986205 has been studied in three completed Phase 1 trials: NCT02658890 in advanced cancer and melanoma, NCT03192943 in advanced tumors in Japan, and NCT03374228 in healthy participants. A fourth trial, NCT03792750, studied the drug in Chinese patients with advanced malignant solid tumors.
BMS-986205 is an investigational drug being studied in combination with nivolumab and ipilimumab, which are approved immunotherapies. However, BMS-986205 itself is a distinct small molecule and is not known to be the same as any other approved drug.
BMS-986205 is a small molecule being developed for oncology. While its specific molecular target is not disclosed in the available information, it is being studied in combination with checkpoint inhibitors like nivolumab and ipilimumab to treat advanced cancers.